C-Reactive Protein Testing Market Expected to Reach $3,568.69 Million by 2030

According to a new report published by Allied Market Research, titled, " C-Reactive Protein Testing Market by, Assay Type, Application and Region: Global Opportunity Analysis and Industry Forecast, 2021–2030," the global C-reactive protein testing market size was valued at $2,765.07 million in 2020, and is projected to reach $3,568.69 million by 2030, registering a CAGR of 2.4% from 2021 to 2030.

C-reactive protein (CRP), an acute phase protein is primarily induced during acute phase of an inflammatory/infectious process by the action of Interleukin IL-6 on the gene responsible for CRP transcription. C-reactive protein test is used to determine concentration of CRP in blood plasma. CRP is an acute inflammatory protein that can multiply up to 1,000-fold in areas of infection or inflammation. The test is used to determine the infection and other medical conditions. The test does not specify direct cause of inflammation, but indicates the level of inflammation caused by other factors. It is a reliable early indicator of inflammation or injury.

Growth of the C-reactive protein testing market is majorly driven, owing to rise in prevalence of chronic diseases such as diabetes, rheumatoid arthritis, endometriosis, cardiovascular disease, inflammatory bowel disease, and other diseases. Increase in unhealthy lifestyle, poor eating habits, rise in stress, and adoption of sedentary lifestyle has led to increase in number of chronic diseases globally.

For instance, according to the Centers for Disease Control and Prevention in 2021, one in every four adults in the U.S., which is 23.7% or approximately 58.5 million people, have arthritis. Arthritis is more common in women (23.5%) than in men (18.1%) and more common in adults with fair/poor health (40.5%) than in those with excellent/very good health (15.4%). Furthermore, prevalence of arthritis rises with age. In the coming decades, the prevalence of doctor-diagnosed arthritis is expected to rise significantly. By 2040, an estimated 78.4 million adults aged 18 and older, which is 25.9% of the projected total adult population will have doctor-diagnosed arthritis, up from 58.5 million adults from 2013 to 2015. Thus, rise of such cases is expected to significantly increase the number of CRP testing and further drive the c-reactive protein testing market growth during the forecast period.

In addition, technological advancements for CRP testing, development, and launch of various products further drive the market growth. For instance, in September 2021, HORIBA UK Limited launched its new generation Microsemi CRP point-of-care hematology analyzer. It is nearly 25% more compact and includes improved software with network connectivity, resulting in improved usability and increased memory capacity. A new parameter, granulocytes-to-lymphocytes ratio (GLR), has been added to its suite of 20 parameters to support COVID-19 patient assessment. All of this contributes toward increased functionality of new Microsemi CRPs and diagnostic efficiency in determining whether an infection or inflammation is viral or bacterial and determining the appropriate antibiotic therapy at the point-of-care. Its delivers results in just four minutes, combined with comprehensive data management and enables clinicians to initiate more rapid treatment decisions. Thus, launch of such products further propel growth of the C-reactive protein testing market.

However, lack of public awareness is expected to impede the market growth. Conversely, high market potential in the untapped emerging economies and government initiatives for health awareness is expected to provide many opportunities during the forecast period.

By assay type, the c-reactive protein testing market is segmented into enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), immunoturbidimetric assay, and others. The immunoturbidimetric assay segment generated maximum revenue in 2020, accounting $1276.57 million. The chemiluminescence immunoassay (CLIA) segment is expected to witness highest CAGR of 3.60% during the forecast period.

Depending on application, the c-reactive protein testing market is divided into diabetes, rheumatoid arthritis, cardiovascular disease, inflammatory bowel disease, and others. The cardiovascular disease segment dominated the market in 2020, with $1,793.88 million and is expected to witness CAGR of 2.10% during the forecast period.

North America accounted for a majority of the global c-reactive protein testing market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in prevalence of inflammatory diseases, increase in unhealthy lifestyle, development of new solutions for detection, presence of key players, and rise in healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in chronic diseases, rise in R&D activities, and increase in investments in the healthcare sector in the region

Key Findings Of The Study

• By assay type, immunoturbidimetric assay was the highest contributor to the c-reactive protein testing market in 2020.
• By application, cardiovascular disease segment exhibited the highest growth in 2020, and is expected to continue this trend during the forecast period.
• By region, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.